Luspatercept
| Clinical data | |
|---|---|
| Pronunciation | /lʊsˈpætərsɛpt/ luus-PAT-ər-sept |
| Trade names | Reblozyl |
| Other names | ACE-536, luspatercept-aamt |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620043 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C3350H5070N906O1044S38 |
| Molar mass | 75958.99 g·mol−1 |
Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes.
The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.